| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Protein Science, Vol 3, Issue 8 1169-1177, Copyright © 1994 by Cold Spring Harbor Laboratory Press
ARTICLE |
L. CUI, D. F. CARNEY and T. E. HUGLI
Institute of Basic Medical Science, Chinese Academy of Medical Sciences, Molecular Biology, 5 Dong Dan San Tiao, Beijing, China
The anaphylatoxin C5a is a pro-inflammatory factor generated from C5 during complement activation. C5a derived from rat C5 exhibits significantly greater potency compared to C5a from other species. Rat C5a was 25-fold more potent than human C5a for eliciting spasmogenic contraction of guinea pig ileum. Proteolytic removal of the C-terminal arginine of C5a (C5a(desArg)) reduced spasmogenic potency of rat C5a by only 4-fold compared to a 3,000-fold reduction for human C5a(desArg). In addition, rat C5a(desArg) was 50-fold more potent than human C5a(desArg) in a guinea pig vascular permeability (in vivo) assay and as a chemotactic factor for human neutrophils. C5a and C5a(desArg) were purified from zymosan-activated rat serum. Rat C5a, like human C5a, is glycosylated but contains 77 amino acid residues instead of the 74 residues of human C5a. Comparison of the primary structures of rat and human C5a indicated differences at 30 positions including an insert of 3 residues (LLH) in the rat molecule between residue positions 3 and 5 in human C5a. Insertion of residues LLH between Gln-3 and Lys-4 in a recombinant human C5a molecule using site-directed mutagenesis failed to enhance potency. Synthetic C-terminal analogues of rat C5a proved to be measurably more potent than the corresponding human C5a analogues (Ember JA et al., 1993, Protein Sci 2(Suppl 1):159 [Abstr]). We conclude that multiple sequence differences in the C-terminal effector portion and/or elsewhere in rat C5a, but not the LLH insert, account for the significant enhancement in potency of rat C5a over C5a from other species.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Nemali, D. W. Siemsen, L. K. Nelson, P. L. Bunger, C. L. Faulkner, P. Rainard, K. A. Gauss, M. A. Jutila, and M. T. Quinn Molecular analysis of the bovine anaphylatoxin C5a receptor J. Leukoc. Biol., August 1, 2008; 84(2): 537 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurizaki, S. Okazaki, S. D. Sanderson, D. Colcher, C. A. Enke, M. A. Tempero, and J. Baranowska-Kortylewicz Potentiation of Radioimmunotherapy with Response-Selective Peptide Agonist of Human C5a J. Nucl. Med., July 1, 2002; 43(7): 957 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mack, K. Jungermann, O. Gotze, and H. L. Schieferdecker Anaphylatoxin C5a Actions in Rat Liver: Synergistic Enhancement by C5a of Lipopolysaccharide-Dependent {alpha}2-Macroglobulin Gene Expression in Hepatocytes Via IL-6 Release from Kupffer Cells J. Immunol., October 1, 2001; 167(7): 3972 - 3979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Schieferdecker, G. Schlaf, M. Koleva, O. Gotze, and K. Jungermann Induction of Functional Anaphylatoxin C5a Receptors on Hepatocytes by In Vivo Treatment of Rats with IL-6 J. Immunol., May 15, 2000; 164(10): 5453 - 5458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Czermak, A. B. Lentsch, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement Am. J. Pathol., May 1, 1999; 154(5): 1513 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Czermak, V. Sarma, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward In Vitro and In Vivo Dependency of Chemokine Generation on C5a and TNF-{alpha} J. Immunol., February 15, 1999; 162(4): 2321 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
